Clear Street raised the firm’s price target on Protagonist Therapeutics (PTGX) to $91 from $74 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q3 report.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics Advances Pipeline Amid Financial Loss
- Promising Developments and Strategic Progress at Protagonist Therapeutics Drive Buy Rating
- Protagonist Therapeutics reports Q3 EPS (62c), consensus (64c)
- PTGX Earnings this Week: How Will it Perform?
- Protagonist Therapeutics price target raised to $88 from $76 at Truist